Slow Release Formulation of Cisplatin Reduces Nephrotoxicity in Rats
Author Information
Author(s): G. Los, W. Kop, M.J.M. Deurloo
Primary Institution: The Netherlands Cancer Institute
Hypothesis
Can a slow release formulation of cisplatin reduce nephrotoxicity while maintaining antitumour efficacy in rats?
Conclusion
Using a slow drug release system for cisplatin reduced renal toxicity but did not improve the antitumour response.
Supporting Evidence
- Creatinine levels in plasma decreased when cisplatin was incorporated into the slow release system.
- Survival time increased for all treatments compared to the control group.
- Platinum concentrations in tumors were comparable after both treatment methods after 7 days.
Takeaway
This study found that a special way of giving a cancer drug can help protect the kidneys, but it didn't make the drug work better against the tumors.
Methodology
Rats with peritoneal tumors were treated with either free cisplatin or a slow release formulation, and their survival and kidney function were measured.
Limitations
The study may have been affected by the rapid clearance of the drug from the peritoneal cavity, leading to uneven drug distribution.
Participant Demographics
Male WAG/Rij rats, 8-12 weeks old.
Statistical Information
P-Value
<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website